Dermatology Doctors in Onalaska, WI Accepting Medicare

10 Dermatology doctors found. Showing 1 - 10

Dr. April Lee Farrell, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3111 Gundersen Dr, Onalaska, WI 54650 Phone: 608-775-8100

Abigail L Taub, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3111 Gundersen Dr, Onalaska, WI 54650 Phone: 608-775-8100

John Kohorst, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 191 Theater Rd, Onalaska, WI 54650 Phone: 608-785-0940

Dr. Rebecca Danhof, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 191 Theater Rd, Onalaska, WI 54650 Phone: 608-392-5000

Dr. Hans E. Von Weiss, DO Dermatology Medicare: Accepting Medicare Assignments Practice Location: 191 Theater Road, Onalaska, WI 54650 Phone: 608-392-5000

Dr. Stephen B Webster, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 3111 Gundersen Dr, Onalaska, WI 54650 Phone: 608-775-2625

Michael J White, MD Dermatology Medicare: Medicare Enrolled Practice Location: 191 Theater Rd, Onalaska, WI 54650 Phone: 608-785-0940

Dr. Thomas Joseph Hogarty, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 3111 Gundersen Dr, Onalaska, WI 54650 Phone: 307-752-7546

James C Baumgaertner, MD Dermatology Medicare: Medicare Enrolled Practice Location: 3111 Gundersen Dr, Onalaska, WI 54650 Phone: 608-775-8630

Karl R Noll, MD Dermatology Medicare: Medicare Enrolled Practice Location: 3111 Gundersen Dr, Onalaska, WI 54650 Phone: 608-775-2382

News Archive

European Patent Office issues notice of intent to grant patent for Nuvo Research's PENNSAID 2%

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that the European Patent Office has issued a notice of Intention to Grant a European Patent that provides protection for the Company's PENNSAID 2% product.

Novel heart attack treatment results presented at premier USA cardiology forum

Regenerative medicine company Mesoblast Limited (ASX:MSB; USADR:MBLTY) has announced that positive preclinical trial results were presented at the American Heart Association's annual conference in Chicago showing that the company's proprietary "off-the-shelf" stem cells can be injected simply, safely, and effectively into the coronary arteries after a heart attack to prevent heart failure.

Increased UV radiation can affect human fertility, new NTNU study finds

A new study from the Norwegian University of Science and Technology shows that increased UV radiation can have an effect on human fertility over generations.

New tools developed to enrich cereal products with bioactive compounds

The bioactive compounds of cereals are concentrated in the peripheral layers of the grains (bran) but most of them have a low bio-accessibility. In the HEALTHGRAIN project of the European Union, new tools for process monitoring were developed that support commercial implementation of innovative milling techniques including partial grain debranning, fine grinding and classification of grain fractions, resulting in flours and ingredients with enhanced nutritional properties.

Read more Medical News

› Verified 5 days ago